The Influence of day-to Day BPV on Long-term Adverse Outcomes in Patients Ischemic Stroke

Completed

• Conditions: Stroke

• Registration Number: NCT02663557
• Lead Sponsor: Zhu Shi

Brief Summary

Stroke is one of the most devastating disorder worldwide. Hypertension has been confirmed to be a major modifiable risk factor for stroke.Even the casual visit hypertension has been managed ideally,there is still surplus risk for stroke re-attack.The purpose of this study is to explore whether variation of 24-hour ambulatory and visit-to-visit blood pressure variability (BPV) contribute to recurrent stroke.

Detailed Description

System hypertension has been reported to play the most important role in the development of stroke,and the anti-hypertension therapy is regarded as the cornerstone for stroke secondary prevention. However, even though some proper measures have been taken,there is still surplus risk for recurrent stroke. Recently the variation of system blood pressure has been focused as the candidate of another risk factor.Up to date,this hypothesis remains an intense debate and few studies has been done to clarify it.Besides, the definition of BPV and measurement of BPV parameters are still beyond conformity.In the current study, the long-term and short-term BPV will be taken respectively for patients with prior stroke. Bsed on these parameters, the cohort will be followed up for average 2 years. The predefined outcome include composite cardiovascular events, neuropsychiatric wording, and mortality during followup.

Study Timeline

• Study Start: 2014-07
• Study First Submitted: 2016-01-21
• Study First Submitted QC: 2016-01-21
• Study First Posted: 2016-01-26
• Primary Completion: 2016-06
• Study Completion: 2017-03
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-18
• Last Update Posted: 2017-05-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Exclusion Criteria

• comorbidity of dementia ( including AD, PDD, FTLD, VaD and so on )
• coexisting severe systematic diseases on admission such as acute coronary syndrome, malignant tumor, plasma dialysis therapy for renal failure, cirrhosis, rheumatic disease that would influence mortality.
• discharge with severe sequelae with mRS>5

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mortality	12 months	all cause death

Secondary Outcome Measures

Name	Time	Method
microvascular events	12 months	cognition and psychological decline
macrovascular events	12 months	stroke, including recurrent ischemic stroke and intra-cerebral hemorrhage, coronary artery events and peripheral artery occlusion

Trial Locations

Locations (1)

Dongguan Peoples' Hospital; 🇨🇳 Dongguan, Guangdong, China